NeoStem Announces New Publication That Supports Positive Results of AMR-001 for Treatment of AMI
Posted: October 10, 2012 at 9:12 pm
NEW YORK, Oct. 10, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NBS), an emerging leader in the fast growing cell therapy market, announced today that a new article published by the International Scholarly Research Network provides further evidence that AMR-001, NeoStem's lead product candidate through its Amorcyte subsidiary, appears capable of preserving heart muscle function following a large myocardial infarction. Amorcyte demonstrated in its Phase 1 trial that AMR-001 preserved heart muscle function when a therapeutic dose of cells was administered. No patient experienced a deterioration in heart muscle function who received 10 million cells or more whereas 30 to 40 percent of patients not receiving a therapeutic dose did. The new study shows that cardiac muscle function sparing effects are evident even earlier after treatment than previously shown.
The article titled "Assessment of myocardial contractile function using global and segmental circumferential strain following intracoronary stem cell infusion after myocardial infarction: MRI Feature Tracking Feasibility Study" by Sabha Bhatti, MD, et al. appears in ISRN Radiology Volume 2013, Article ID 371028 and is published online at http://www.isrn.com/journals/radiology/2013/371028. The publication by Dr. Bhatti and colleagues, including Dr. Andrew Pecora, Chief Medical Officer of NeoStem, supports the finding that AMR-001 preserves heart function. Previously, Amorcyte, a NeoStem subsidiary, showed that six months after STEMI AMR-001 improved blood flow to the heart and preserved heart muscle. By using cardiac magnetic resonance imaging, specifically measuring circumferential strain of the left ventricle, the authors show that AMR-001's effects are evident by three months after STEMI.
AMR-001's angiogenic and anti-apoptotic mechanisms of action indicate that preservation of heart muscle function should start within weeks and be evident in fewer than 6 months. This publication, based on blinded analysis of Amorcyte's Phase 1 data, confirms the expected time course for AMR-001's mechanism of action. In the context of previously published results, these effects are durable.
Amorcyte is developing AMR-001, a cell therapy for the treatment of cardiovascular disease, and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving cardiac function and preventing adverse clinical events after a large myocardial infarction.
About NeoStem, Inc.
NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.
Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, as mentioned above, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.
Forward-Looking Statements for NeoStem, Inc.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its CDMO business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to (i) the Company's ability to manage its business despite operating losses and cash outflows, (ii) its ability to obtain sufficient capital or strategic business arrangement to fund its operations, including the clinical trials for AMR-001, (iii) successful results of the Company's clinical trials of AMR-001 and other cellular therapeutic products that may be pursued, (iv) demand for and market acceptance of AMR-001 or other cell therapies if clinical trials are successful and the Company is permitted to market such products, (v) establishment of a large global market for cellular-based products, (vi) the impact of competitive products and pricing, (vii) the impact of future scientific and medical developments, (viii) the Company's ability to obtain appropriate governmental licenses and approvals and, in general, future actions of regulatory bodies, including the FDA and foreign counterparts, (ix) reimbursement and rebate policies of government agencies and private payers, (x) the Company's ability to protect its intellectual property, (xi) the company's ability to successfully divest its interest in Erye, and (xii) matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
See more here:
NeoStem Announces New Publication That Supports Positive Results of AMR-001 for Treatment of AMI
- CAR T-Cell Immunotherapy for ALL - National Cancer Institute - October 27th, 2015
- Gene Therapy and Cell Therapy Defined | ASGCT - American ... - October 20th, 2015
- StemCell Therapy MD - October 3rd, 2015
- Stem Cell Therapy in Mexico - May 8th, 2015
- Autologous Adipose Tissue Derived Stromal Vascular Fraction Cells Application In Patients - Video - May 1st, 2015
- Platelet Rich Plasma Injections For Chronic Pain Relief May Help You Avoid Sugery - Video - May 1st, 2015
- Stem Cell Treatment for COPD | StemRx Bioscience Solutions - Video - April 25th, 2015
- Stem Cell Therapy Market in Asia-Pacific to 2018 - Video - April 22nd, 2015
- Phytoscience Philipine celebrity Share good effect of stem cell Therapy - Video - April 18th, 2015
- STEM CELL therapy incredible results for severe MS - Video - April 18th, 2015
- Clinical Benefits of Stem Cell Therapy - Video - April 18th, 2015
- NYC Health & Longevity Center Now Offering Stem Cell Therapy to Avoid Joint Replacement - April 13th, 2015
- U.S. Stem Cell Clinic: What Conditions Can Be Treated? - Video - April 12th, 2015
- Stem Cell Therapy In USA - April 12th, 2015
- Stem Cell Therapy for Pain - Now Available at Columbia Pain Management - Video - April 11th, 2015
- What is Stem Cell Therapy- Trinity Spine and Wellness Center New Port Richey - Video - April 11th, 2015
- U.S. Stem Cell Clinic: How long will my recovery take? - Video - April 11th, 2015
- U.S. Stem Cell Clinic: Stem Cell Banking - Video - April 11th, 2015
- U.S. Stem Cell Clinic: What is Stem Cell Therapy? - Video - April 11th, 2015
- U.S. Stem Cell Clinic: How is Stem Cell Therapy Performed? - Video - April 11th, 2015
- U.S. Stem Cell Clinic: When should I expect to see results? - Video - April 11th, 2015
- Can PRP and Stem Cell Therapy Help You? | Orlando Orthopaedic Center - Video - April 3rd, 2015
- Induced Pluripotent Stem Cell (iPSC) Industry Complete Report 2015 - 2016 - April 3rd, 2015
- Stem Cell Therapy for Neuromuscular Diseases | InTechOpen - March 31st, 2015
- Arizona Pain Stem Cell Institute Now Offering Stem Cell Therapy to Help Patients Avoid Hip and Knee Replacement - March 31st, 2015
- Center of Regenerative Orthopedics in South Florida Now Offering Stem Cell Therapy to Help Avoid Hip and Knee ... - March 31st, 2015
- Ask Dr. Lemper | Stem Cell Therapy Treatments - Video - March 29th, 2015
- No stem cell treatment for public servant's dodgy knee - March 26th, 2015
- Stem Cell Therapy - Lilli Donovan - Video - March 25th, 2015
- Stem Cell Research - Stem Cell Treatments - Treatments ... - March 25th, 2015
- What is "Stem cell therapy" ? | Steps in PRP Treatment : TV5 News - Video - March 23rd, 2015
- Stem cell clinics under govt scanner - March 22nd, 2015
- SuperCells at Centre for Life - Video - March 21st, 2015
- Knee arthritis 3 years after stem cell therapy by Harry Adelson, N.D. - Video - March 21st, 2015
- Stem Cell Injection Treatment Stem Cell Therapy - Video - March 21st, 2015
- stem cell therapy di indonesia Jakarta tangerang serpong bsd bintaro - Video - March 21st, 2015
- The Alpha Clinic for Cell Therapy and Innovation | City of Hope - Video - March 20th, 2015
- Amniotic Stem Cell Therapy Discussed by R3 (844) GET-STEM - Video - March 20th, 2015
- Stem cell therapy may help treat type 2 diabetes - March 20th, 2015
- CAR T-Cell Therapy - Nebraska Medicine - Video - March 18th, 2015
- Stem Cell Therapy- Sci Video2 - Video - March 18th, 2015
- Stem Cell Therapy Now Being Offered for NonHealing Wounds at Telehealth's Three Regenerative Medicine Clinics - March 17th, 2015
- Stem Cell Research & Therapy | Full text | Amnion-derived ... - March 15th, 2015
- High-Dose Immunosuppressive Therapy and Autologous ... - March 15th, 2015
- Miracle stem cell therapy reverses multiple sclerosis - Video - March 14th, 2015
- Hip and shoulder arthritis six months after bone marrow stem cell therapy by Harry Adelson ND - Video - March 13th, 2015
- Stem Cell Therapy Network - Video - March 12th, 2015
- Stem Cell Therapy Cream - Video - March 9th, 2015
- BioLogic Stem Cell Therapy Cream - Video - March 8th, 2015
- World Over - 2015-02-26 - Vatican latest, ISIS, stem cell therapy, Ray Flynn with Raymond Arroyo - Video - March 8th, 2015
- Shoulder Labral Tear Repair Using Stem Cell Therapy - Orthopedic Surgeon, Dr. Wade McKenna - Video - March 6th, 2015
- What Makes Riordan-McKenna Institute Different? Stem Cell Therapy for Orthopedics - Video - March 6th, 2015
- Overcoming Knee Replacement Surgery Faster Using Amniotic Tissue-Enhanced Stem Cell Therapy - Video - March 6th, 2015
- Stem Cell Therapy in Osteo Arthritis Knee - Video - March 6th, 2015
- stem cell therapy helps avoiding knee surgery - Video - March 6th, 2015
- Stem cell therapy in AKI Dr Mohamed Kamal - Video - March 6th, 2015
- Stem Cell Therapy for Bone Fractures - Board-Certified Orhopedic Surgeon, Wade McKenna DO - Video - March 5th, 2015
- Procedure Overview - The STEM CELL ORTHOPEDIC INSTITUTE of Texas - Video - March 5th, 2015
- Glen Wysoki at The STEM CELL ORTHOPEDIC INSTITUTE of Texas - Video - March 5th, 2015
- Shoulder/Hip torn labrum 2 years and 5 months (respectively) after stem cell therapy by Adelson - Video - March 1st, 2015
- Animal cells for a younger you - March 1st, 2015
- 'Miracle' stem cell therapy reverses multiple sclerosis - March 1st, 2015
- Stem cell therapy a boon to Parkinson's patients - February 27th, 2015
- Stem Cell Research & Therapy | Full text | Aromatic ... - February 23rd, 2015
- Why Stem Cell Therapy? - Video - February 22nd, 2015
- What is Bone Marrow Aspirate Concentrate (BMAC) in Stem Cell Therapy? - Video - February 21st, 2015
- Dr Ellis hosts seminar on Stem Cell Therapy & Facial Rejuvenation - Video - February 17th, 2015
- Hip arthritis 3.5 years after stem cell therapy by Harry Adelson, N.D. - Video - February 16th, 2015
- How about Stem Cell Therapy for LBD, Nova Cells Institute stem cells - Video - February 14th, 2015
- Stem Cell Therapy for Erectile Dysfunction - Alvarado Hospital - Video - February 14th, 2015
- Cell Therapy may have just raised $1M, but will crowdfunding have a lasting place in biotech? - February 10th, 2015
- International Stem Cell completes cell bank manufacturing for Parkinson's disease clinical trial - February 4th, 2015
- Tampa stem cell clinic is long on promises, not evidence - February 1st, 2015
- Denver Regenerative Medicine - What is regenerative medicine? - Video - January 30th, 2015
- Cell Trials - January 26th, 2015
- "She's Happy" RMG's next Stem Cell Miracle - Video - January 21st, 2015
- Nutech Mediworld - Pioneering human embryonic stem cell therapy - Video - January 21st, 2015
- Stem Cell Therapy | Recent Strides Quell Stem Cell Debate - Video - January 20th, 2015
- Dr Sherif Stem cell therapy on OA - Video - January 18th, 2015
- Live100 Hospitals - Stem Cell Therapy - Video - January 16th, 2015